Enanta Pharmaceuticals, Inc. Stock price

Equities

ENTA

US29251M1062

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-03-27 pm EDT 5-day change 1st Jan Change
16.53 USD +3.64% Intraday chart for Enanta Pharmaceuticals, Inc. +14.00% +75.66%
Sales 2024 * 68.81M Sales 2025 * 73.31M Capitalization 350M
Net income 2024 * -110M Net income 2025 * -116M EV / Sales 2024 * 5.08 x
Net cash position 2024 * - Net cash position 2025 * - EV / Sales 2025 * 4.77 x
P/E ratio 2024 *
-3.17 x
P/E ratio 2025 *
-3.35 x
Employees 145
Yield 2024 *
-
Yield 2025 *
-
Free-Float 93.9%
More Fundamentals * Assessed data
Dynamic Chart
Oppenheimer Adjusts Enanta Pharmaceuticals Price Target to $17 From $21, Maintains Perform Rating MT
Transcript : Enanta Pharmaceuticals, Inc., Q1 2024 Earnings Call, Feb 07, 2024
Earnings Flash (ENTA) ENANTA PHARMACEUTICALS Reports Q1 Revenue $18M, vs. Street Est of $21.9M MT
Enanta Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended December 31, 2023 CI
Transcript : Enanta Pharmaceuticals, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-10-2024 09:45 AM
Enanta Pharmaceuticals, Inc. Announces Retirement of Nathaniel S. Gardiner as Senior Vice President and General Counsel, Effective on or Before March 31, 2024 CI
Enanta Pharmaceuticals, Inc.(NasdaqGS:ENTA) dropped from NASDAQ Biotechnology Index CI
Sector Update: Health Care Stocks Mixed Pre-Bell Friday MT
Sector Update: Health Care MT
Enanta Pharmaceuticals Files $150 Million Mixed Shelf MT
Oppenheimer Adjusts Enanta Pharmaceuticals Price Target to $21 From $25, Maintains Perform Rating MT
HC Wainwright Cuts Enanta Pharmaceuticals' Price Target to $28 From $30, Maintains Buy Rating MT
Transcript : Enanta Pharmaceuticals, Inc., Q4 2023 Earnings Call, Nov 20, 2023
Earnings Flash (ENTA) ENANTA PHARMACEUTICALS Reports Q4 Revenue $18.9M, vs. Street Est of $17.5M MT
Enanta Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended September 30, 2023 CI
More news
1 day+3.64%
1 week+14.00%
Current month+15.03%
1 month+17.65%
3 months+71.30%
6 months+43.74%
Current year+75.66%
More quotes
1 week
13.86
Extreme 13.86
17.01
1 month
13.47
Extreme 13.47
17.01
Current year
9.24
Extreme 9.24
17.01
1 year
8.08
Extreme 8.08
41.45
3 years
8.08
Extreme 8.08
102.00
5 years
8.08
Extreme 8.08
102.00
10 years
8.08
Extreme 8.08
127.77
More quotes
Managers TitleAgeSince
Chief Executive Officer 67 03-06-30
Director of Finance/CFO 68 03-08-31
Chief Tech/Sci/R&D Officer 50 22-08-07
Members of the board TitleAgeSince
Director/Board Member 63 20-06-28
Director/Board Member 63 16-11-17
Chairman 80 13-11-24
More insiders
Date Price Change Volume
24-03-27 16.53 +3.64% 476,790
24-03-26 15.95 +14.42% 477,223
24-03-25 13.94 -4.46% 132,434
24-03-22 14.59 -0.27% 392,276
24-03-21 14.63 +0.90% 396,626

Delayed Quote Nasdaq, March 27, 2024 at 04:00 pm EDT

More quotes
Enanta Pharmaceuticals, Inc. is a biotechnology company. The Company is engaged in the discovery and development of small molecule drugs, with an emphasis on treatments for viral infections. Its primary wholly owned research and development programs are in virology, namely respiratory syncytial virus (RSV), SARS-CoV-2, Hepatitis B virus (HBV) and Human metapneumovirus (hMPV). The Company has discovered glecaprevir, the second of two protease inhibitors discovered and developed for the treatment of chronic infection with hepatitis C virus (HCV). Glecaprevir is a co-formulated direct-acting antiviral (DAA), combination treatment for HCV, which is marketed under the tradenames MAVYRET and MAVIRET. Its lead clinical candidate for the treatment of chronic infection with HBV, is EDP-514. Its lead clinical candidate for COVID-19 is EDP-235. The Company's clinical stage program for RSV, with two compounds in clinical trials includes EDP-938 and EDP-323.
Calendar
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
8
Last Close Price
16.53 USD
Average target price
20.88 USD
Spread / Average Target
+26.29%
Consensus
  1. Stock
  2. Equities
  3. Stock Enanta Pharmaceuticals, Inc. - Nasdaq